Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome

Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome

Gain of function (GOF) mutations affecting the inflammasome component NLRC4 are known to cause early-onset macrophage activation syndrome (MAS) and neonatal enterocolitis. Here we report a patient with a NLRC4 GOF mutation presenting with neonatal MAS efficiently treated with a combination of anakin...

Full description

Bibliographic Details
Main Authors: Julie Barsalou, Annaliesse Blincoe, Isabel Fernandez, Dorothée Dal-Soglio, Lorie Marchitto, Silvia Selleri, Elie Haddad, Aissa Benyoucef, Fabien Touzot
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Immunology
Subjects:
macrophage activation syndrome
NLRC4
inflammasome
mTOR
rapamycin
IL-18
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02162/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02162/full

Similar Items